Yes, Prolia Treats Osteoporosis
Prolia (denosumab) is FDA-approved to treat postmenopausal osteoporosis in women at high risk for fracture, increasing bone density and reducing vertebral, nonvertebral, and hip fracture risk.[1] It's also approved for osteoporosis in men at high fracture risk and glucocorticoid-induced osteoporosis.[1]
How Prolia Works for Bone Loss
Prolia is a monoclonal antibody that binds RANKL, a protein involved in osteoclast activity, which breaks down bone. By inhibiting RANKL, it slows bone resorption and boosts bone mineral density, unlike bisphosphonates that directly target osteoclasts.[1][2]
Who Gets Prescribed Prolia?
Doctors prescribe it for:
- Postmenopausal women with osteoporosis and high fracture risk.
- Men with osteoporosis.
- Patients on long-term glucocorticoids causing bone loss.
It's given as a subcutaneous injection every 6 months, typically after trying oral bisphosphonates fail or aren't tolerated.[1]
Common Side Effects Patients Report
Back pain, muscle pain, high cholesterol, and bladder infections occur in over 10% of users. Serious risks include jaw osteonecrosis (rare, ~0.04%), atypical femur fractures, and severe hypocalcemia—patients need calcium and vitamin D supplements.[1][2] Skin infections and eczema are also noted.
How Prolia Compares to Fosamax or Reclast
| Drug | Type | Dosing | Fracture Reduction | Key Drawback |
|------|------|--------|---------------------|-------------|
| Prolia | RANKL inhibitor (injection) | Every 6 months | Hip: 40%, vertebral: 68% | Stopping requires transition to avoid rebound fractures [2] |
| Fosamax (alendronate) | Bisphosphonate (oral) | Weekly | Hip: 51%, vertebral: 47% | GI upset, long bone retention [1] |
| Reclast (zoledronic acid) | Bisphosphonate (IV) | Yearly | Hip: 41%, vertebral: 70% | Flu-like symptoms post-infusion [1] |
Prolia often suits patients with poor oral adherence but requires careful discontinuation planning.[2]
When Does Prolia's Patent Expire?
Core patents on denosumab expired in 2017 in the US, but formulation and method-of-use patents extend protection to 2025 (US 8,058,418) and beyond for some indications. Biosimilars face challenges; no US approvals yet, but development is underway.3
What Happens If You Stop Prolia?
Bone density drops rapidly (up to 6-8% vertebral loss in 12 months), with higher fracture risk. Guidelines recommend transitioning to bisphosphonates for 1-2 years.[2]
[1]: FDA Label for Prolia (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125320s205lbl.pdf)
[2]: American College of Rheumatology Guidelines (https://rheumatology.org/osteoporosis-guideline)